Abstract 12056: Incidence of Actionable Events on Implantable Cardiac Monitors: A Prospective Study Comparing Reveal LINQTM and Confirm RxTM Implantable Cardiac Monitors

IntroductionImplantable cardiac monitors (ICM) are increasingly being used to detect and treat arrhythmias in various clinical settings such as cryptogenic stroke. However, the incidence of actionable events in ICMs is unknown. HypothesisConfirm RxTM has more actionable event detection rate than Reveal LINQTM MethodsWe prospectively studied 411 patients who received Reveal LINQTM (Medtronic Inc., Dublin, Ireland) or Confirm RxTM (Abbott, Sylmar, CA) ICM system for diagnosis of actionable arrhythmic events. Actionable arrhythmic events were defined as atrial fibrillation (AF) requiring anticoagulation, pauses requiring pacemaker, and tachycardia requiring ablation or medication changes. All actionable events were adjudicated for accuracy. ResultsThis study evaluated 411 patients with baseline characteristics of52.1% females, an average age of 65.81 years, and an average body mass index of 29.9 kg/m2. Reasons for ICM implants were, in descending ordercryptogenic stroke (44.3%), syncope (35%), and palpitations (20.9%). The Reveal LINQTM was used in 56.4% (n=232) of patients and Confirm RxTM was used in the other 43.6% (n=179). On univariate analysis, the composite outcome of actionable events were similar in both groups (Reveal LINQTM 19% vs Confirm RxTM 19%, p>0.9). The individual actionable event outcome were also similar in both groupsAF (Reveal LINQTM 11% vs Confirm RxTM 8.5%, p=0.6), pauses (Reveal LINQTM 1.3% vs Confirm RxTM 4.0%, p=0.2), tachycardia (Reveal LINQTM 6.0% vs Confirm RxTM 5.6%, p>0.9). However, the time to actionable event or last follow-up was significantly reduced (p